The Contributions of Lithium and Clozapine for the Prophylaxis and Treatment of Suicidal Behavior

Advances in Biological Psychiatry

Volumn 30, Issue , 2015, Pages 145-160

  Müller Oerlinghausen, Bruno ^a   Lewitzka, Ute ^b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84945125257     PISSN: 03787354     EISSN: 16622774     Source Type: Book Series    
DOI: 10.1159/000434747     Document Type: Article

References (95)

1. Healy D, Whitaker C: Antidepressants and suicide: risk-benefit conundrums. J Psychiatry Neurosci 2003; 28: 331-337
2. Holvey C, Connolly A, Taylor D: Psychiatric side effects of non-psychiatric drugs. Brit J Hospital Med 2010; 1: 432-436
3. Stubner S, Grohmann R, v. Strahelndorff I, Ruther E, Moller HJ, Muller-Oerlinghausen B, Engel RR, Horvath A, Greil W: Suicidality as rare adverse event of antidepressant medication: report from the AMSP multicenter drug safety surveillance project. J Clin psychiatry 2010; 71: 1293-1307
4. Muller-Oerlinghausen B: Suizidales Verhalten als unerwunschte Arzneimittelwirkung. Suizidprophylaxe 2014; 41: 106-112
5. Oxenkrug G, Turski W, Zgraika W, Weinstock J, Ruthazer R, Summergrad P: Disturbances of tryptophan metabolism and risk of depression in HCV patients treated with IFN-α. J Infect Dis Ther 2014; 2:131
6. Menke A, Domschke K, Czamara D, Klengel T, Hennings J, Lucae S, Baune BT, Arolt V, Muller-Myhsok B, Holsboer F, Binder EB: Genome-wide association study of antidepressant treatment-emergent suicidal ideation. Neuropsychopharmacology 2012; 37: 797-807
7. Bschor T, Muller-Oerlinghausen B: Antidepressiva verringern nicht das Risiko von Suiziden oder Suizidversuchen bei depressiven Patienten. Arzneiverord Prax 2014; 41: 2-5
8. Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hutton B: Association between suicide attempts and selective serotonin uptake inhibitors: systematic review of randomised controlled studies. BMJ 2005; 330: 396
9. Gibbons RD, Brown CD, Hur K, Davis J, Mann JJ: Suicidal thoughts and behaviour with antidepressant treatment: reanalysis of the randomized placebocontrolled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012; 69: 580-587
10. Lewitzka U, Severus E, Bauer R, Ritter P, Muller-Oerlinghausen B, Bauer M: The suicide protective effects of lithium: more than 20 years of evidence. Int J Bipolar Dis, in press.
11. Tsuang MT, Woolson RF: Excess mortality in schizophrenia and affective disorders. Do suicides and accidental deaths solely account for this excess? Arch Gen Psychiatry 1978; 35: 1181-1185
12. Weeke A: Causes of death in manic depressives; in Schou M, Stromgren E (eds): Origin, Prevention and Treatment of Affective Disorders. London, Academic Press, 1979, pp 289-299
13. Hagnell O, Lanke J, Rorsman B: Suicide rates in the Lundby study: mental illness as a risk factor for suicide. Neuropsychobiology 1981; 7: 248-253
14. Tuckman J, Youngman W: Identifying suicide with groups among attempted suicide. Public Health Rep 1963; 78: 763-766
15. Motto I: Suicide attempts: a longitudinal view. Arch Gen Psychiatry 1965; 13: 516-520
16. Guze SB, Robins E: Suicide in primary affective disorders. Br J Psychiatry 1970; 117: 437-438
17. Goodwin FK, Jamison KR: Manic-depressive illness. New York, Oxford University Press, 1990
18. WHO: Preventing Suicide: A Resource for General Physicians. Geneva, WHO, 2000. http://www.who. int/mental-health/media/en/56.pdf?ua=1
19. Isometsa E: Suicidal behaviour in mood disorders-who, when, and why? Can J Psychiatry 2014; 59: 120-130
20. Harris EC, Barraclough B: Excess mortality of mental disorder. Br J Psychiatry 1998; 173: 11-53
21. Ahrens B, Muller-Oerlinghausen B, Schou M, Wolf T, Alda M, Grof E, Grof P, Lenz G, Simhandl C, Thau K, Wolf R, Moller HJ: Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium-prophylaxis. J Affect Disord 1995; 33: 67-75
22. Barraclough B: Suicide prevention, recurrent affective disorder and lithium. Br J Psychiatry 1972; 121: 391-392
23. Muller-Oerlinghausen B, Muser-Causemann B, Volk J: Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 1992; 25: 261-270
24. Felber W, Kyber A: Suizide und Parasuizide wahrend und ausserhalb einer Lithiumprophylaxe; in Muller-Oerlinghausen B, Berghofer A (eds): Ziele und Ergebnisse der medikamentosen Prophylaxe affektiver Psychosen. Stuttgart/New York, Thieme, 1994, pp 53-59
25. Coppen A, Standish-Barry H, Bailey J, Houston G, Silcocks P, Hermon C: Does lithium reduce the mortality of recurrent mood disorders? J Affect Disord 1991; 23: 1-7
26. Ahrens B, Muller-Oerlinghausen B: Einfluss der Lithiumprophylaxe auf die Mortalitat von affektiven Psychosen; in Lungershausen E, Kaschka WP, Witkowsli RJ (eds): Affektive Psychosen. Stuttgart/New York, Schattauer, 1990, pp 334-337
27. Coppen A: Depression as a lethal disease: prevention strategies. J Clin Psychiatry 1994; 55: 37-45
28. Muller-Oerlinghausen B, Ahrens B, Grof E, Grof P, Lenz G, Schou M, Simhandl C, Thau K, Volk J, Wolf R, Wolf T: The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizo-Affective illness. Acta Psychiatr Scand 1992; 86: 218-222
29. Muller-Oerlinghausen B, Wolf T, Ahrens B, Schou M, Grof E, Grof P, Lenz G, Simhandl C, Thau K, Wolf R: Mortality during initial and during later lithium treatment: a collaborative study by IGSLI. Acta Psychiatr Scand 1994; 90: 295-297
30. Bocchetta A, Ardau R, Burrai C, Chillotti C, Quesada G, del Zompo M: Suicidal behaviour on and off lithium prophylaxis in a group of patients with prior suicide attempts. J Clin Psychopharmacol 1998; 18: 384-389
31. Baldessarini RJ, Tondo L, Hennen J: Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999; 60: 77-84
32. Nilsson A: Mortality in recurrent mood disorders during periods on and off lithium. A complete population study in 362 patients. Pharmacopsychiatry 1995; 28: 8-13
33. Schou M: The effect of prophylactic lithium treatment on mortality and suicidal behavior: a review for clinicians. J Affect Disord 1998; 50: 253-259
34. Kallner G, Lindelius R, Petterson U, Stockman O, Tham A: Mortality in 497 patients with affective disorders attending a lithium clinic of after having left it. Pharmacopsychiatry 2000; 33: 8-13
35. Angst J, Angst F, Gerber-Werder R, Gamma A: Suicide in mood-disorder patients with and without long-term medication: a 40 to 44 years follow-up. Arch Suicide Res 2005; 9: 279-300
36. Vestergaard P, Aagaard J: Five-year mortality in lithium-treated manic-depressive patients. J Affect Disord 1991; 21: 33-38
37. Brodersen A, Licht RW, Vestergaard P, Olesen AV, Mortensen PB: Sixteen-year mortality in patients with affective disorder commenced on lithium. Br J Psychiatry 2000; 176: 429-433
38. Coryell W, Arndt S, Turvey C, Endicott J, Solomon D, Mueller T, Leon AC, Keller M: Lithium and suicidal behaviour in major affective disorder: a casecontrol study. Acta Psychiatr Scand 2001; 104: 193-197
39. Tondo L, Jamison KR, Baldessarini RJ: Effect of lithium maintenance on suicidal behavior in major mood disorders. Ann N Y Acad Sci 1997; 836: 339-351
40. Cipriani A, Pretty H, Hawton K, Geddes JR: Lithium in the prevention of suicidal behaviour and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162: 1805-1819
41. Cipriani A, Hawton K, Stockton S, Geddes JR: Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-Analysis. BMJ 2013; 346:f3646
42. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J: Decreased risk of suicides and attempts during long-term lithium treatment: a metaanalytic review. Bipolar Disord 2006; 8: 625-639
43. Lauterbach E, Felber W, Muller-Oerlinghausen B, Ahrens B, Bronisch T, Meyer T, Kilb B, Lewitzka U, Hawellek B, Quante A, Richter K, Brooks A, Hohagen F: Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo-controlled, 1-year trial. Acta Psychiatr Scand 2008; 118: 469-479
44. Rombold F, Lauterbach E, Felber W, Muller-Oerlinghausen B, Ahrens B, Bronisch T, Kilb B, Lewitzka U, Richter K, Brooks A, Heuser I, Hohagen F, Quante A: Adjunctive lithium treatment in the prevention of suicidal behaviour in patients with depression and comorbid personality disorder. Int J Psychiatry Clin Pract 2014; 18: 300-303
45. Thies-Flechtner K, Muller-Oerlinghausen B, Seibert W, Walther A, Greil W: Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Pharmacopsychiatry 1996; 29; 103-107
46. Greil W, Ludwig-Mayerhofer W, Erazo N, Schochlin C, Schmidt S, Engel RR, Czernik A, Giedke H, Muller-Oerlinghausen B, Osterheider M, Rudolf GAE, Sauer H, Tegeler J, Wetterling T: Lithium versus carbamazepine in the maintenance treatment of bipolar disorders-A randomised study. J Affect Disord 1997; 43: 151-161
47. Goodwin FK: Anticonvulsant therapy and suicide in affective disorders. J Clin Psychiatry 1999; 60: 89-93
48. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D: Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290: 1467-1473
49. Collins JC, McFarland BH: Divalproex, lithium and suicide among Medicaid patients with bipolar disorder. J Affect Disord 2008; 107: 23-28
50. Oquendo MA, Galfalvy HC, Currier D, Grunebaum MF, Sher L, Sullivan GM, Burke AK, Harkavy-Freedman J, Sublette ME, Parsey RV, Mann JJ: Treatment of suicide attempters with bipolar disorder: a randomised clinical trial comparing lithium and valproate in the prevention of suicidal behaviour. Am J Psychiatry 2011; 168: 1050-1056
51. Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B; Trial 144 Study Investigators: Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (trial 144; a randomized controlled study). J Clin Psychiatry 2011; 72: 1452-1464
52. Khan A, Khan SR, Hobus J, Faucett J, Mehra V, Giller EL, Rudolph RL: Differential pattern of response in mood symptoms and suicide risk measures in severely ill depressed patients assigned to citalopram with placebo or citalopram combined with lithium: role of lithium levels. J Psychiatr Res 2011; 45: 1489-1496
53. Baldessarini RJ, Tondo L, Hennen J: Reduced suicide risk during long-term treatment with lithium. Ann NY Acad Sci 2001; 932: 24-43
54. Muller-Oerlinghausen B: Lithium long-term treatment-does it act via serotonin? Pharmacopsychiatry 1985; 18: 214-217
55. Muller-Oerlinghausen B: Die Wirkung von Lithium auf serotoninerge Funktionen; in Muller-Oerlinghausen B, Greil W, Berghofer A (eds): Die Lithiumtherapie. Berlin/Heidelberg/New York, Springer, 1997, pp 61-68
56. Nilsson A: The anti-Aggressive actions of lithium. Rev Contemp Pharmacother 1993; 4: 269-285
57. Muller-Oerlinghausen B, Lewitzka U: Lithium reduces pathological aggression and suicidality: a mini-review. Neuropsychobiology 2010; 62: 43-49
58. Ohmura Y, Tsutsui-Kimura I, Kumamoto H, Minami M, Izumi T, Yamaguchi T, Yoshida T, Yoshioka M: Lithium, but not valproic acid or carbamazepine, suppresses impulsive-like action in rats. Psychopharmacology 2012; 219: 421-432
59. Kovacsics CE, Gould TD: Shock-induced aggression in mice is modified by lithium. Pharmacol Biochem Behav 2010; 94: 380-386
60. Muhlbauer HD, Muller-Oerlinghausen B: Fenfluramine stimulation of serum cortisol in patients with major affective disorders and healthy controls: further evidence for a central serotonergic action of lithium in man. J Neural Transm 1985; 61: 81-94
61. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, Bernstein HG, Bogerts B: Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. Psychiatr Res 2008; 42: 151-157
62. Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindquist D, Samuelsson M, Lundberg K, Postolache TT, Traksman-Bendz L, Guillemin GJ, Brundin L: Connecting inflammation with glutamate agonism. Neuropsychopharmacology 2013; 38: 743-752
63. Steiner J, Bogerts B, Samyai Z, Walter M, Gos T, Bernstein HG, Myint AM: Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity. World J Biol Psychiatry 2012; 13: 437-492
64. Kovacsics CE, Gottesman II, Gould TD: Lithiums antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Ann Rev Pharmacol Toxicol 2009; 49: 175-198
65. Linden M, Zaske H, Ahrens B: Correlates of suicidal ideation in general healthcare patients-results of the WHO Collaborative Study on Psychological Problems in General Health Care (WHO-PPGHC). Int J Psychiatry Clin Pract 2003; 7: 17-25
66. Painuly N, Sharan P, Mattoo SK: Relationship of anger and anger attacks with depression: a brief review. Eur Arch Psychiatry Clin Neurosci 2005; 255: 215-222
67. van Praag HM: Anxiety and increased aggression as pacemakers of depression. Acta Psychiatr Scand 1998; 393: 81-88
68. Lewitzka U, Jabs B, Fulle M, Holthoff V, Juckel G, Uhl I, Kittel-Schneider S, Reif A, Reif-Leonhard C, Gruber O, Djawid B, Goodday S, Haussmann R, Pfennig A, Ritter P, Conell J, Severus E, Bauer M: Does lithium reduce suicidal ideation and behavior? A protocol for a randomized, placebo-controlled multicenter trial of lithium plus treatment as usual (TAU) in patients with suicidal major depressive episode. BMC Psychiatry 2015; 15: 117
69. Kropf D, Muller-Oerlinghausen B: Changes in learning, memory, and mood during lithium treatment. Acta Psychiatr Scand 1979; 59: 97-124
70. Kropf D, Muller-Oerlinghausen B: Effects of lithium on visual perception in manic depressive patients without acute symptomatology. Neuropsychobiology 1986; 15: 34-42
71. Muller-Oerlinghausen B: Towards a neurophysiological model of the mode of action of lithium. Pharmacopsychiatry 1987; 20: 192-194
72. Ulrich G, Herrmann WM, Hegerl U, Muller-Oerlinghausen B: Effects of lithium on the dynamics of electroencephalographic vigilance in healthy subjects. J Affect Disord 1990; 20: 19-25
73. Classen W: Der psychologische Zugang zur Wirkungsweise von Lithium; in Muller-Oerlinghausen B, Greil W, Berghofer A (eds): Die Lithiumtherapie. Nutzen, Risiken, Alternativen, ed 2. Berlin/Heidelberg/New York, Springer, 1997, pp 118-136
74. Ahrens B, Muller-Oerlinghausen B: Does lithium exert an independent anti-suicidal effect? Pharmacopsychiatry 2001; 34 : 132-136
75. Ohgami H, Tero T, Shiotsuki I, Ishii N, Iwata N: Lithium levels in drinking water and risk of suicide. Br J Psychiatry 2009; 194: 464-465
76. Kapusta ND, Mossaheb N, Etzersdorfer E, Hlavin G, Thau K, Willeit M, Praschak-Rieder N, Sonneck G, Leithner-Dziubas K: Lithium in drinking water and suicide mortality. Br J Psychiatry 2011; 198: 346-350
77. Helbich M, Leithner M, Kapusta ND: Geospatial examination of lithium in drinking water and suicide mortality. Int J Health Geogr 2012; 13: 11-19
78. Giotakos O, Nisianakis P, Tsouvelas G, Giakalou VV: Lithium in the public water supply and suicide mortality in Greece. Biol Trace Elem Res 2013; 156: 376-379
79. Bluml V, Regier MD, Hlavin G, Rocket IR, Konig F, Vyssoki B, Bschor T, Kapusta ND: Lithium in the public water supply and mortality in Texas. J Psychiatr Res 2013; 47: 407-411
80. Kabacs N, Memon A, Obinwa T, Stochl J, Perez J: Lithium in drinking water and suicide rates across the East of England. Br J Psychiatry 2011; 198: 406-407
81. Vita A, de Peri L, Sacchetti E: Lithium in drinking water and suicide prevention: a review of the evidence. Int Clin Psychopharmacol 2015; 30: 1-5
82. Joffe RT: Editorial: does lithium save lives? J Psychiatry Neurosci 2004; 29: 9
83. Ahrens B, Muller-Oerlinghausen B: Die antisuizidale und mortalitatssenkende Wirkung von Lithium; in Muller-Oerlinghausen B, Greil W, Berghofer A (eds): Die Lithiumtherapie. Berlin/Heidelberg/New York, Springer, 1997, pp 262-277
84. Meltzer HY: Suicide in schizophrenia: risk factors and clozapine treatment. J Clin Psychiatry 1998; 59: 15-20
85. Kerwin RW, Bolonna AA: Is clozapine antisuicidal? Expert Rev Neurother 2004; 4: 187-190
86. Aguilar EJ, Siris SG: Do antipsychotic drugs influence suicidal behavior in schizophrenia? Psychopharmacol Bull 2007; 40: 128-142
87. Wasserman D, Rihmer Z, Rujescu D, Sarchiapone M, Sokolowski M, Titelman D, Zalsman G, Zemishlany Z, Carli V; European Psychiatric Association: The European Psychiatric Association (EPA) guidance on suicide treatment and prevention. Eur Psychiatry 2012; 27: 129-141
88. Meltzer HY, Okayli G: Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152: 183-190
89. Walker AM, Lanza LL, Arellano R, Rothman KJ: Mortality in current and former users of clozapine. Epidemiology 1997; 8: 671-677
90. Meltzer HY, Alphs L, Green AI, Atamura AC, Anand R, Bertold A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lendenmayer JP, Potkin S; International Suicide Prevention Trial Study Group: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT ). Arch Gen Psychiatry 2003; 60: 82-91
91. Reutfors J, Bahmanyar S, Jonsson EG, Brandt L, Boden R, Ekbom A, Osby U: Medication and suicide risk in schizophrenia: a nested case-control study. Schizophr Res 2013; 150: 416-420
92. Paris J, Zweig-Frank H: A 27-year follow-up of patients with borderline personality disorder. Compr Psychiatry 2001; 42: 482-487
93. Zarzar T, McEvoy J: Clozapine for self-injurious behavior in individuals with borderline personality disorder. Ther Adv Psychopharmacol 2013; 3: 272-274
94. Celada P, Bortolozzi A, Artigas F: Serotonin 5-HT 1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs 2013; 27: 703-716
95. Nugent AC, Carlson PJ, Bain EE, Eckelman W, Herscovitch P, Manji H, Zarate CA, Drevets WC: Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression. J Psychopharmacol 2013; 27: 894-902